Esperion Posts Positive Phase III Bempedoic Acid Results, But Future Fixed-Dose Data Are Key
Esperion reported positive results from the third of five Phase III studies expected to read out this year, but data for a bempedoic acid/ezetimibe fixed-dose combo expected in August may be the key to the drug's commercial future.
You may also be interested in...
Final Phase III study for pivotal package of cholesterol drug bempedoic acid shows LDL-lowering efficacy and a clean safety profile, paving the way for filings in the first half of 2019.
'Study 4' results may support a label claim related to reducing inflammation – measured through the high sensitivity C-reactive protein (hsCRP) marker – down the line, the company told investors.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.